Thrive Capital Management (Pennsylvania)’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.77M Sell
87,664
-1,077
-1% -$52.4K 0.9% 38
2026
Q1
$3.81M Buy
88,741
+7,909
+10% +$340K 0.83% 53
2025
Q4
$3.54M Buy
80,832
+19,155
+31% +$792K 0.79% 62
2025
Q3
$2.55M Buy
+61,677
New +$2.48M 0.66% 62

Other funds holding EXEL

Thrive Capital Management (Pennsylvania)'s EXEL Position: Q2 2026 in Review

Thrive Capital Management (Pennsylvania) reduced its Exelixis (EXEL) stake by 1.2% in Q2 2026, selling an estimated $52.4K and leaving 87,664 shares worth $4.77M. The position accounts for 0.9% of the portfolio, ranked #38.

Thrive Capital Management (Pennsylvania) first reported a position in EXEL in Q3 2025 and has held it in 4 quarters since. 760 funds tracked by Wall St. Rank hold EXEL as of Q2 2026.

  • Thrive Capital Management (Pennsylvania) held 87,664 shares of Exelixis worth $4.77M as of Q2 2026.
  • Thrive Capital Management (Pennsylvania) sold 1,077 Exelixis shares in Q2 2026, an estimated $52.4K.
  • Exelixis made up 0.9% of Thrive Capital Management (Pennsylvania)'s portfolio in Q2 2026, its #38 holding.
  • Thrive Capital Management (Pennsylvania) first reported a position in Exelixis in Q3 2025 and has held it in 4 quarters since.
  • 760 funds tracked by Wall St. Rank held Exelixis as of Q2 2026.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q2 2026, filed 5 Aug 2026.